foxo4-dri p53 The disordered transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI | Excenen PharmaTech
FOXO4 DRI Excenen PharmaTech Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv Analysis of the 2 predicted binding pockets of FOXO4 DRI. (A) Surface Download Scientific Diagram Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine FOXO4 DRI Research Peptide 15mg
Pay in 4 interest-free payments of $5.82 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9





